Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol)

Last updated: April 16, 2026
Sponsor: University of California, Los Angeles
Overall Status: Planned

Phase

N/A

Condition

Seizure Disorders (Pediatric)

Unverricht-lundborg Syndrome

Dravet Syndrome

Treatment

Fenfluramine

Clinical Study ID

NCT04437004
ZX008-1800
  • Ages > 2
  • All Genders

Study Summary

The purpose of this research study is to (1) provide access to fenfluramine for patients with intractable epilepsy associated with Dravet syndrome, and (2) evaluate the safety of fenfluramine.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Genetic diagnosis of Dravet syndrome with intractable seizures despite failing all available medications for seizures.

Study Design

Treatment Group(s): 1
Primary Treatment: Fenfluramine
Phase:
Study Start date:
Estimated Completion Date:

Study Description

The purpose of this research study is to (1) provide access to fenfluramine for patients with intractable epilepsy associated with Dravet syndrome, and (2) evaluate the safety of fenfluramine.

Connect with a study center

  • University of California, Los Angeles

    Los Angeles, California 90095-1752
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.